At InSingulo, we specialize in the characterization of drug interactions with complex targets down to the single molecule level. Our biosensing technology allows for drug profiling on membrane proteins embedded in their native environment. We enable drug screening programs against membrane proteins and other challenging therapeutic targets.
InSingulo was founded in 2017 following a collaboration between Chalmers University of Technology and AstraZeneca, bringing a new class of biosensing technology to overcome some of the toughest challenges in drug discovery.
insingulo.com
Location: Sweden, Stockholm